12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Colobreathe colistimethate sodium regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Colobreathe colistimethate sodium from Forest Labs to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >